Aura Biosciences Inc.

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

7:00 a.m. May 12, 2023

- BusinessWire - BZX

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

4:10 p.m. May 11, 2023

- BusinessWire - BZX

Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM

2:02 a.m. April 25, 2023

- EQS Group AG

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

4:10 p.m. March 15, 2023

- BusinessWire - BZX

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

8:00 a.m. Feb. 16, 2023

- BusinessWire - BZX

Aura Biosciences to Participate in Upcoming Investor Conferences

8:00 a.m. Feb. 9, 2023

- BusinessWire - BZX

Aura Biosciences Announces Pricing of Public Offering of Common Stock

9:50 p.m. Nov. 30, 2022

- BusinessWire - BZX

Aura Biosciences Announces Proposed Public Offering of Common Stock

5:01 p.m. Nov. 30, 2022

- BusinessWire - BZX

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

8:00 a.m. Nov. 10, 2022

- BusinessWire - BZX

Aura Biosciences to Participate in Upcoming Investor Conferences

7:01 a.m. Nov. 3, 2022

- BusinessWire - BZX

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform

7:05 a.m. Oct. 4, 2022

- GlobeNewswire

Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022

11:32 a.m. Oct. 3, 2022

- EQS Group AG

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

7:00 a.m. Oct. 3, 2022

- BusinessWire - BZX

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

6:00 a.m. Oct. 3, 2022

- BusinessWire - BZX

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

7:00 a.m. Sept. 28, 2022

- BusinessWire - BZX

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

7:00 a.m. Sept. 27, 2022

- BusinessWire - BZX

Interim Results for the Six Months Ended 30 June 2022

2:01 a.m. Aug. 10, 2022

- EQS Group AG